ALLMedicine™ Amyotrophic Lateral Sclerosis Center
Research & Reviews 5,996 results
https://doi.org/10.1186/s13073-021-01006-6 10.1038/nature20413 10.1212/NXG.0000000000000398 10.1038/ng.3622 10.1038/s41467-017-00471-1 10.1038/ng.3211 10.1038/ng.3955 10.1038/ncomms14774 10.1038/ng.3626 10.1016/j.neuron.2018.02.027 10.1038/s42003-020-01251-2 10.1016/j.celrep.2020.108323 10.1038/nature22366 10.1038/s41586-020-2188-x 10.1007/s00415-013-6877-3 10.1038/nature16549 10.1016/j.ajhg.2013.10.012 10.1038/nn.4587 10.1038/ng.3538 10.1038/s41467-017-01261-5 10.1038/s41467-019-11181-1 10.1038/ng.3404 10.1038/s41588-018-0081-4 10.1038/nature15393 10.1371/journal.pcbi.1004219 10.1093/bioinformatics/btr260 10.1126/science.aat8127 10.1038/mp.2013.93 10.1038/nature11247 10.1038/nature14248 10.1038/nature24277 10.1038/s41588-018-0089-9 10.1038/ng.2213 10.1038/s41467-018-04558-1 10.1038/nn.4399 10.1038/nn.4632 10.1111/j.1471-4159.2011.07432.x 10.1126/science.aat8464 10.1038/ng.3506 10.1093/bioinformatics/btw198 10.1016/j.clinph.2020.04.005 10.1038/s41525-020-0118-3 10.1371/journal.pone.0198874 10.1371/journal.pgen.0030161 10.1126/science.282.5391.1145 10.1038/ncomms7626 10.1111/bph.14657 10.1371/journal.pone.0018373 10.1038/s41467-018-06111-6 10.1016/j.jns.2005.02.004 10.1083/jcb.200304128 10.1038/nm.2901 10.1002/ana.23946 10.1212/NXI.0000000000000829 10.1093/brain/awy353 10.1093/nar/gky837 10.1371/journal.pgen.1002431 10.1073/pnas.95.25.14863 10.1038/s41588-021-00913-z 10.1016/j.bbadis.2010.09.011 10.4103/1673-5374.241445 10.3892/ijmm.2017.3049 10.1016/0891-5849(94)90079-5 10.1074/jbc.274.15.10349 10.1016/j.stemcr.2018.04.020 10.1038/s41591-018-0140-5 10.1016/j.neuron.2019.07.014 10.1074/jbc.M401907200 10.1038/nn.3801 10.1172/JCI118522 10.1042/cs0830343 10.1161/CIRCULATIONAHA.110.000034 10.3389/fncel.2015.00203 10.1016/j.bbadis.2006.03.008 10.3390/ijms15022475 10.1007/s00401-005-1019-3 10.1038/s41467-018-04114-x 10.1016/j.ebiom.2020.102980 10.1038/s41586-020-2308-7 10.1016/S1474-4422(13)70061-9 10.1016/j.omtn.2019.02.001
Genome Medicine; Restuadi R, Steyn FJ et. al.
Jan 20th, 2022 - Amyotrophic lateral sclerosis (ALS) is a complex, late-onset, neurodegenerative disease with a genetic contribution to disease liability. Genome-wide association studies (GWAS) have identified ten risk loci to date, including the TNIP1/GPX3 locus ...
https://doi.org/10.1007/s12640-021-00469-0 10.3389/fnins.2018.00466 10.1038/ncb3064 10.1016/j.freeradbiomed.2009.11.018 10.3390/cells9061505 10.1074/jbc.M115.680090 10.1111/j.1474-9726.2008.00432.x 10.1038/s41598-021-92369-8 10.1038/s41598-019-39739-5 10.1016/j.cell.2012.03.042 10.1016/j.nbd.2016.05.011 10.1016/j.exger.2013.01.011 10.1016/S1474-4422(07)70270-3 10.1126/science.8209258 10.1002/(SICI)1097-4547(19980701)53:1%3C66::AID-JNR7%3E3.0.CO;2-H 10.1002/dvg.20777 10.1038/s41582-020-00434-z 10.1073/pnas.1415518111 10.1080/14660820510026162 10.1002/ana.410440518 10.1016/j.freeradbiomed.2004.12.021 10.1371/journal.pone.0033529 10.1212/WNL.62.10.1758 10.3389/fnmol.2020.00093 10.1097/01.wnr.0000073685.00308.89 10.1016/j.cell.2013.12.010 10.1016/j.tcb.2015.10.014 10.1016/j.freeradbiomed.2012.02.043 10.1016/j.abb.2007.05.001
Neurotoxicity Research; Evans RC, Chen L et. al.
Jan 20th, 2022 - The degeneration and death of motor neurons lead to motor neuron diseases such as amyotrophic lateral sclerosis (ALS). Although the exact mechanism by which motor neuron degeneration occurs is not well understood, emerging evidence implicates the ...
https://doi.org/10.1002/jcu.23093
Journal of Clinical Ultrasound : JCU; Bongioanni P
Jan 20th, 2022 - Diaphragm ultrasonography as a tool in assessing respiratory muscle involvement in amyotrophic lateral sclerosis/motor neuron disease.|2022|Bongioanni P,|
https://doi.org/10.1073/pnas.2114314119
Proceedings of the National Academy of Sciences of the Un... Kanagaraj R, Mitter R et. al.
Jan 20th, 2022 - Mutations in the SETX gene, which encodes Senataxin, are associated with the progressive neurodegenerative diseases ataxia with oculomotor apraxia 2 (AOA2) and amyotrophic lateral sclerosis 4 (ALS4). To identify the causal defect in AOA2, patient-...
https://doi.org/10.1016/j.neurobiolaging.2021.12.002
Neurobiology of Aging; Tohnai G, Nakamura R et. al.
Jan 19th, 2022 - DNAJC7 has recently been identified as an amyotrophic lateral sclerosis (ALS) gene via large-scale exome analysis, and its involvement in ALS is still unclear in various populations. This study aimed to determine the frequencies and characteristic...
Guidelines 3 results
https://doi.org/10.1002/mus.26408
Muscle & Nerve; Pattee GL, Plowman EK et. al.
Jan 9th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...
https://doi.org/10.1016/j.clnu.2017.09.003
Clinical Nutrition (Edinburgh, Scotland); Burgos R, Bretón I et. al.
Dec 25th, 2017 - Neurological diseases are frequently associated with swallowing disorders and malnutrition. Moreover, patients with neurological diseases are at increased risk of micronutrient deficiency and dehydration. On the other hand, nutritional factors may...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764728
Neurology Miller RG, Jackson CE et. al.
Oct 14th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...
Drugs 17 results see all →
Clinicaltrials.gov 184 results
https://clinicaltrials.gov/ct2/show/NCT04856982
Jan 14th, 2022 - The primary objective of this study is to evaluate the efficacy of BIIB067 when initiated in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to ...
https://clinicaltrials.gov/ct2/show/NCT02437110
Jan 13th, 2022 - Objective: In this Phase I, proof-of-concept study, we aim to determine whether an antiretroviral regimen approved to treat human immunodeficiency virus (HIV) infection would also suppress levels of Human Endogenous Retrovirus-K (HERV-K) found to ...
https://clinicaltrials.gov/ct2/show/NCT04569084
Jan 12th, 2022 - To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS) based on the change in ALS Functional Rating Scale- Revised (ALSFRS-R) score from baseline up to Week 48:
https://clinicaltrials.gov/ct2/show/NCT05178810
Jan 5th, 2022 - Multicenter, multinational, double-blind, randomized (2:1), placebo-controlled Phase III study to investigate the efficacy and safety of 100 mg FAB122 once daily as oral formulation in ALS patients.
https://clinicaltrials.gov/ct2/show/NCT04394871
Dec 16th, 2021 - Objective: Amyotrophic lateral sclerosis type 4 (ALS4) is an inherited form of motor neuron disease caused by mutation in the senataxin (SETX) gene. The main goal of this study will be to collect clinical and molecular biomarkers from patients wit...
News 334 results
https://www.medscape.com/viewarticle/966717
Jan 17th, 2022 - Dr Simon Witzel Long-term add-on treatment with intravenous (IV) edaravone is not associated with any change in the progression of amyotrophic lateral sclerosis (ALS), new research shows. These findings contradict those from the drug trial the US ...
https://www.medscape.com/viewarticle/964853
Dec 15th, 2021 - National Football League players are nearly four times more likely to develop amyotrophic lateral sclerosis (ALS) than men in the general population, with long-term players at greatest risk, a new study shows. The findings are the latest to show i...
https://www.medpagetoday.com/neurology/generalneurology/95120
Oct 19th, 2021 - The antimalarial drug hydroxychloroquine (HCQ) was associated with reduced disability worsening in people with primary progressive multiple sclerosis (MS), a phase II trial showed. (Annals of Neurology) The FDA approved injectable high-dose naloxo...
https://www.medpagetoday.com/neurology/generalneurology/94613
Sep 21st, 2021 - Elevated levels of HDL and apolipoprotein A1 were linked to a lower risk of amyotrophic lateral sclerosis (ALS), U.K. Biobank data showed. (Journal of Neurology, Neurosurgery, & Psychiatry) Also from the U.K. Biobank cohort: age-related macular de...
https://www.medscape.com/viewarticle/958730
Sep 14th, 2021 - Elevated levels of high-density lipoprotein (HDL) and apolipoprotein A1 (apoA1) are associated with a reduced risk for amyotrophic lateral sclerosis (ALS), new research shows. The study also linked a higher ratio of total cholesterol to HDL with a...
